A Phase 4 interventional study of Ilumya Injectable Product in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.
Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing tildrakizumab in Psoriasis — 2 open to participants now, 4 under way, 2 of them phase 3. tildrakizumab · Psoriasis.
Among the 16 studies testing tildrakizumab in Psoriasis, this one is the 13th largest by planned enrollment, is one of 7 that started in 2020, is one of 8 in phase 4, and was the 11th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →2 of the 16 studies testing tildrakizumab in Psoriasis are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
tildrakizumab: first FDA approval 2018 (ILUMYA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 7 · Phase 4 8
First in 2010; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 117 across the 16 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Psoriasis Treatment Center of Central New Jersey is the lead sponsor of 17 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey: 5 open now, 5 under way, none of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 4, and was the 10th registered.
Psoriasis Treatment Center of Central New Jersey’s Psoriasis studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing tildrakizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Psoriasis Treatment Center of Central New Jersey’s 13 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16.
At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy.
Patients will continue to be evaluated at weeks 20 and 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
Drug: Ilumya Injectable Product
IL-23 injection
Body surface area
evaluation of body surface area percentage affected by psoriasis where 1 palm is equivalent to 1%
Time frame: 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2020 (actual). Primary completion is estimated for Dec 2020, 8 months after the start.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 8 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tildrakizumab
Psoriasis Treatment Center of Central New Jersey